In the fourth quarter of 2025, Mayo Clinic Laboratories expanded its test catalog with several innovative new tests, including:

• GFAPP | Glial Fibrillary Acidic Protein (GFAP), Plasma
  • Serves as a biomarker for astrocyte activation following brain injury or neurological disorders.
  • Correlates with severity of neural damage and neuroinflammation.
  • Supports evaluation of neurodegenerative disease progression and traumatic brain injury.

• 5NTD | 5'-Nucleotidase, Serum
  • Aids in diagnosing hepatobiliary disease and bile duct obstruction.
  • Differentiates elevated alkaline phosphatase due to liver disease versus bone pathology.
  • Serves as a specific biomarker for liver-related conditions when used with other enzyme assays.
• ADMAB | ADAMTS 13 Antibody, Plasma
  • Identifies anti-ADAMTS13 IgG antibodies in suspected thrombotic thrombocytopenic purpura.
  • Assists in distinguishing congenital versus immune-mediated TTP.
  • Supports prognosis and treatment decisions through antibody characterization.
• CODES | Codeine and Metabolite, Serum
  • Evaluates codeine and morphine levels to confirm compliance with prescribed therapy.
  • Assists in distinguishing therapeutic use from potential misuse or diversion.
  • Offers interpretive ranges for clinical assessment.
• GPNMB | Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB), Technical Component Only
  • Screens kidney tumors for genetic alterations involving TSC1, TSC2, MTOR, and TFE3/TFEB.
  • Serves as a marker for angiomyolipoma, renal cell carcinomas with TFE3/TFEB or TSC/MTOR alterations, and TFE3-rearranged mesenchymal tumors.
  • Supports tumor classification and diagnostic evaluation through immunohistochemical staining.
• GUSAP | Guselkumab Quantitation with Antibodies, Serum
  • Monitors guselkumab levels in patients with ulcerative colitis, Crohn’s disease, and other conditions.
  • Assesses therapeutic drug response and detects antidrug antibodies impacting efficacy.
  • Guides treatment decisions for dose adjustment or therapy transition.
• HCQWB | Hydroxychloroquine, Blood
  • Monitors whole blood hydroxychloroquine levels for compliance and dose adjustment.
  • Assists in managing treatment for lupus, rheumatoid arthritis, and malaria.
  • Helps prevent toxicity and adverse effects associated with long-term use.
• HYDCS | Hydrocodone and Metabolites, Serum
  • Monitors hydrocodone and related metabolites (norhydrocodone, hydromorphone, dihydrocodeine).
  • Confirms adherence to opioid therapy and identifies misuse or abuse.
  • Provides therapeutic ranges for accurate dose evaluation.
• HYDMS | Hydromorphone, Serum
  • Measures hydromorphone levels in serum for compliance and therapeutic monitoring.
  • Helps prevent opioid misuse and supports pain management decisions.
• LCTF | Lactoferrin, Feces
  • Detects fecal lactoferrin as a biomarker for intestinal inflammation.
  • Differentiates inflammatory bowel disease from irritable bowel syndrome.
  • Provides noninvasive monitoring for IBD, reducing the need for invasive procedures.
• MAGE4 | Melanoma-associated antigen-A4 (MAGE-A4), Semi-Quantitative Immunohistochemistry, Manual
  • Detects MAGE-A4 expression in synovial sarcoma and other neoplasms.
  • Screens patients for eligibility for TECELRA (afamitresgene autoleucel) immunotherapy.
  • Utilizes immunohistochemistry to identify cancer testis antigen expression.
• METSP | MET (SP44), Semi-Quantitative Immunohistochemistry, Manual
  • Assesses MET protein expression in non-small cell lung cancer and other tumors.
  • Helps identify patients eligible for MET-targeted therapies, including telisotuzumab vedotin-tllv.
  • Reports percentage of tumor cells with strong (3+) MET expression.
• MORS | Morphine and Metabolite, Serum
  • Measures morphine and hydromorphone concentrations in serum.
  • Verifies adherence to prescribed opioid therapy and discourages misuse.
  • Provides therapeutic range interpretation for clinical monitoring.
• NECT4 | Nectin-4, Semi-Quantitative Immunohistochemistry, Manual
  • Detects nectin-4 overexpression in bladder cancer and other malignancies.
  • Identifies tumors potentially responsive to enfortumab vedotin therapy.
  • Provides immunohistochemical evaluation for treatment planning.
• OPATS | Opiate Panel, Free (Unconjugated), Serum
  • Detects and quantifies multiple prescribed opiates and metabolites in serum.
  • Monitors therapeutic efficacy, compliance, and potential misuse or abuse.
  • Supports clinical decision-making for pain management strategies.
• OXYDS | Oxycodone and Metabolites, Serum
  • Detects oxycodone, oxymorphone, and related metabolites in serum.
  • Verifies compliance with prescribed opioid therapy and discourages diversion.
  • Provides therapeutic ranges for clinical interpretation.
• OXYMS | Oxymorphone and Metabolite, Serum
  • Quantifies oxymorphone and noroxymorphone concentrations in serum.
  • Confirms adherence to therapy and aids in monitoring for misuse.
  • Supports individualized pain management through therapeutic range assessment.

Visit our test catalog for more information on new or updated tests and testing algorithms.